Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 MkDaSpVv[3Srb36gRZN{[Xl? NXSzRWgyOiEQvF2= M13ze|EhcA>? MmXUbY5pcWKrdIOgeIhmKExvRF;QRUApOjEEoN88UUkucW6mdXPl[EB1emGwc3nlcpQhTVKNMT:yJJBpd3OyaH;yfYxifGmxbtMg MXqyOlM3OzF7MR?=
C2C12 NIT0NYFHfW6ldHnvckBCe3OjeR?= M1\scFHDqM7:Zz;tcC=> MWexxsBp MlHqZYJwdGm|aHXzJIN6fG:taX7lJJJmdGWjc3Wg[pJwdSCFMlOxNkBugW:2dXLldy=> NWPYS4ZUOjZ{OUGyO|k>
MEFs WT NIrOe|BHfW6ldHnvckBCe3OjeR?= MlfjOeKh|ryP M3n3VVIxKG2rbh?= MlG5Z4F2e2W|IILld4ll\W62IHXufplu\XNic4XjbEBieyCQQVfUMWdHWCxidH:g[Iln\nW|ZTDiZYNsKHSxIITo[UBGWg>? NEPSVlIzPjF7NkCyNy=>
MEFs VAMP7 KO NEGyTHlHfW6ldHnvckBCe3OjeR?= M4P2W|XDqM7:TR?= Ml3BNlAhdWmw NUfydGZo[2G3c3XzJJJme2mmZX70JIVvgnmvZYOgd5VkcCCjczDORWdVNUeIUDygeI8h\GmoZoXz[UBj[WOtIITvJJRp\SCHUh?= MU[yOlE6PjB{Mx?=
SMCs MV3GeY5kfGmxbjDBd5NigQ>? NVzjPJR3OTEEoNM1[{9udA>? M2LiSVAuOTJiaB?= M3iz[GROW09? MVLzbI94eyCjIITy[Y5lKHSxd3Hy[JMh[SCqaXfo[ZIh[2:wY3XueJJifGmxbjDv[kB1cGViRWKvV3IhdmW2d3;yb{BqdiC2aHWgdIVzcW63Y3zlZZIh[XKnYdMg M4n1ZlI3OTd{MEiw
SMCs NH7J[5FHfW6ldHnvckBCe3OjeR?= MUKxNOKhyrWpL33s M3;pNlAuOTJiaB?= M3rrdWROW09? NYTZTIFp[2G3c3XzJIEhfHKjboPp[Y51KEOjMjxCpJJmdGWjc3Wg[pJwdSC2aHWgSXIwW1MEoB?= NID0b2EzPjF5MkC4NC=>
HEMC-1 NUTvT3NyTnWwY4Tpc44hSXO|YYm= NFjnZ2oxNjIEoNM1[{9udA>? NWLEWZNsOjUEoHi= MkfXZ4F2e2W|IHGgbIlocGW{IHnubIljcXSxcomg[YZn\WO2IH;uJIV5d2O7dH;zbZMhfGijbjDuc4Nw\GG8b3zl MnPNNlU6PzJ5NUm=
HUVEC NVHnVXFoTnWwY4Tpc44hSXO|YYm= M4G5N|ExyqEQvF2= M2TNZVHDqGh? MmjHSG1UVw>? MYjhZo9tcXOqZYOgbJlxd3irYT3pcoR2[2WmIILlcIVie2Vib3[gRXRRKG[{b32gZZBq[2GuIHHu[EBj[XOxbHH0[ZJidCC|dYLmZYNmew>? NYC0Sox[OjV7NU[5PFg>
HUVEC M4jBemZ2dmO2aX;uJGF{e2G7 MonLNVDDqM7:TR?= MkHVNeKhcA>? M4ThfGROW09? NWj1OI5McW6lcnXhd4V{yqC2aHWgcpVu[mW{IHHu[EBqdnSnboPpeJkhd2ZiZnz1c5Jme2OnboSgZZJm[XNiZYPw[YNq[WyueTDpckBx\XKrboXjcIVieiC|cHHj[S=> M{TZOlI2QTV4OUi4
Caco-2 M4Lpb2Z2dmO2aX;uJGF{e2G7 MoPhNk42KM7:TR?= M{H6NVMxKG2rbh?= NWf4NpYz[XS2ZX71ZZRmeyC2aHWgWGdHNc7{MT3t[YRq[XSnZDDpcoNz\WG|ZTDpckBUTVKWIH\1coN1cW:w NYPvU5FiOjV7NUS5N|E>
NRK MnrwSpVv[3Srb36gRZN{[Xl? NGrJTXczODEkgJXu[{9udA>? NXXMRXF4POLChXi= MVXEUXNQ NEjhbHFz\XOldXXzJI1qfG:2aXOgdJJw\3Knc4Ppc44> NFXyWVgzPTl2OEW4Oi=>
HeLa NY[5Tm9[TnWwY4Tpc44hSXO|YYm= NV35SIxJOjBy4pEFcocwdWx? MXmzJIg> MmXJSG1UVw>? M4TXZYlv\HWlZYOgeIhmKGG{dHnmbYNq[WxiYoLlZYsufXBib3[geIhmKEexbHfpJINwdXCuZYi= NWnQTHdQOjV7NEi1PFY>
COS MVTGeY5kfGmxbjDBd5NigQ>? M4HxXlEh|rypL33s NHPPOGk{KGh? MV3jc41xdGW2ZXz5JIRqe3CncoPld{B1cGViQWCtNUB{cWewYX|CpC=> MlTONlU6OTV7MEC=
DF1  NX;kNHRwTnWwY4Tpc44hSXO|YYm= NUHVVmxrOcLizszNxsA> NXzERpp[PDhiaB?= NEm0SYZFVVOR NHvVSWFlcXOyZYLz[ZPDqHSqZTDlfI9o\W6xdYOgR3NI[WyQQXPUNkBxem:2ZXnu NIPwWXIzPThyN{C1OC=>
nHDFs  M{TEW2Z2dmO2aX;uJGF{e2G7 MnjYNeKh|ryPwrC= MVKyxsBp NX;6NY5VeHKndnXueJMhfGinIHHzd4Vu[my7IH;mJIN6fG:|b3zpZ{Bkd2G2IIDyc5RmcW6|IH;ueI8hT2:uZ3mgcYVu[nKjbnXz MlLtNlU4PzJ4MU[=
FRT  MmrGSpVv[3Srb36gRZN{[Xl? MnewOUDPxGdxbXy= NUTQ[JJwOsLiaB?= NYHFWWt5[myxY3vzJJRz[W[oaXPrbY5oKHSqcn;1[4ghfGinIFfvcIdqKGOxbYDs[Zgh[nliaX7obYJqfGmwZzDFVk11dy2Jb3znbUB1emGwc4DvdpQ> MXeyOVc3PzFzNR?=
FRT  NHG4fItHfW6ldHnvckBCe3OjeR?= M1LtV|Uh|rypL33s NHK0UWMzyqCq MnrKdJJmfmWwdIOgeIhmKGmwY4LlZZNmKGmwIHPs[YF3\WRizsGgd5VjfW6rdIOge4hmdiCdTnGrYYnDqHejczDy[YR2[2Wm M1HicFI2PzZ5MUG1
HepG2  M{PJPWZ2dmO2aX;uJGF{e2G7 NYnkSFM5OeLCidM1UeKh MWGyOEBp MVvEUXNQ Mlnp[IVkemWjc3XzJJRp\SCuZY\lcEBw\iCSWGKgcXJPSQ>? MYmyOVYyPjV7Nx?=
SMCs MYHGeY5kfGmxbjDBd5NigQ>? MXex{txoN22O NF3OS5g{KGh? M{HIOoFk[3WvdXzheIV{KEOQUGmyJJBzd3SnaX6gbY4hfGinIFXSJINwdXCjcoTt[Y51KGGwZDDuc{Btd26pZYKgZ48udG:lYXzpfoVlKHerdHigeIhmKEexbHfpJI1iemunctMg NEXKVlQzPTV6OUSyOS=>
OB-6 MmTSRZBweHSxc3nzJGF{e2G7 NUL0OXNVOi55wrFOwG0> Ml63OFghcA>? M1\oWolv\HWlZYOgZZBweHSxc3nz NFfj[WczPTV|MkS4NC=>
iPSC-CMs  NHjFVFBHfW6ldHnvckBCe3OjeR?= M3nJfVUxOCCwZz;tcC=> MWG0PEBp M4HS[Ylv[3KnYYPld{B1cGViaX70[Y5{cXS7IH;mJJRp\SCqaXfo[ZIhdW:kaXzpeJkhVEGPUIOgZZQhfGinIHPvd5Qhd2ZidHjlJIxwf2W{IH3vZoltcXS7IIPw[YNq\XN? M{DF[lI2PDh6Nk[2
SP-Nluc M{PUVmZ2dmO2aX;uJGF{e2G7 MnyzOUBu\y:vTB?= MU[2JIg> NHzZO2hFVVORwrC= NYWzc49O[2G3c3XzJIFvKGmwY4LlZZNmKGmwIILldI9zfGW{IHHjeIl3cXS7IHnuJJRp\SCyYYLhd4l1\Q>? NGSwfnczPTN7Mkm5PC=>
PEXEL-Nluc MYfGeY5kfGmxbjDBd5NigQ>? M2jQVlUhdWdxbVy= NVXCW3Q4PiCq M3uw[WROW00EoB?= NFiwcnlk[XW|ZYOgZY4hcW6lcnXhd4UhcW5icnXwc5J1\XJiYXP0bZZqfHliaX6geIhmKHCjcnHzbZRm MY[yOVM6Ojl7OB?=
H1299 MVHGeY5kfGmxbjDBd5NigQ>? NFP0SVIyOCEQvHevcYw> NYntNJRIOjRiaB?= M4Dqcolv\HWlZYOgZZV1d3CqYXf5xsA> M1n3W|I2Ozh6OUew
MDA-MB-231 NHGye|dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVew5qCUPTBizsznM41N M3nNSFQ5KGh? NYD1U5M4TUN3MNMgQUAxNjBzNjFCuYcwdUx? NVv2[4ZGOjV|NU[1Olc>
MDA-MB-231 MY\BdI9xfG:|aYOgRZN{[Xl? M3zHZVAvOSEQvHevcWw> NEfmO3Y1KGh? M2TaTolv\HWlZYOgZZBweHSxc3nz MXmyOVM2PjV4Nx?=
MDA-MB-231 NXvVd3pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrqbVl1OC5yMT:wMlA2KM7:Zz;tUC=> M{j6XVI1KGh? NVTNbolwcW6lcnXhd4V{KHSqZTDmdoFkfGmxbjDv[kB{fWJvR{GgZ4VtdCCmZXLybZM> NGPlPFYzPTN3NkW2Oy=>
MDA-MB-231 MlK2RZBweHSxc3nzJGF{e2G7 MlL6NE4xPeLCk{Gg{txoN22O MVWyOEBp NV;rblRmcW6mdXPld{BRSVKSIDjwc4x6KEGGUD3ybYJwe2VicH;sfY1memG|ZT2xLUBkdGWjdnHn[S=> MnK2NlU{PTZ3Nke=
MDA-MB-231 NXrCZ5Q3TnWwY4Tpc44hSXO|YYm= Mnz0NQKBmzVyIN88[{9uVA>? MonpNlQhcA>? M1Lt[YlvcGmkaYTzJJRp\SCob4LtZZRqd25ib3[gN2Qh[W6mIELEJINwdG:waXXz MXeyOVM2PjV4Nx?=
A172 NID6cnVHfW6ldHnvckBCe3OjeR?= NFfxTlUyOMLizsznM41t MojEOOKhcA>? MoHjSG1UV8Li M3jSdpJme3WudIOgbY4hfGinIILleJJw\3KjZHWgeJJidnOyb4L0JI9nKG[udX;y[ZNk\W62IHfyZY52dGW| MoO4NlUzOzl3MEe=
KMS-6 MmrTSpVv[3Srb36gRZN{[Xl? NYnqXoFwOcLizszNxsA> Ml\iNlQhcA>? MmDR[ZhpcWKrdIOgbIFt\iC2aHWgd4VkemW2aX;uJI9nKGejbHHubY4uVEliYYOg[IllKHSqZTDjc451em:u MUmyOVIzQTF{Nh?=
MEC NFLRc4tHfW6ldHnvckBCe3OjeR?= NUjYdmRDOSEQvF2= NGD0OW8yNjViaB?= MYHjZZV{\XNiYTDkdoFu[XSrYzDk[YNz\WG|ZTDpckB1cGVic4Xy[oFk\SCYRVfGVlI> M2HjflI2OjJ6OEG1
HEK293/hERG MlewSpVv[3Srb36gRZN{[Xl? MUWxNOKh|ryP NUGxc|dsOcLiaB?= MXjy[ZN2dHS|IHnuJIEhfGmvZT3k[ZBmdmSnboSgdoVlfWO2aX;uJI1ifHW{ZTDoSXJIKHC{b4TlbY7DqA>? MkTQNlUzOTh2Nkm=
RBE4 NH:yWFhCeG:ydH;zbZMhSXO|YYm= M2O1fVLDqM7:TR?= NUDzTnRbO+LCk{K0xsBp NFHicHNqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHTldIVv\GWwdHz5 M4jwN|I2OTJ6MEK1
RBE4 M3S0SWZ2dmO2aX;uJGF{e2G7 MVyyxsDPxE1? MViz5qCUOjUEoHi= Ml\PbY5kemWjc3XzJJRp\SC[QmCxJJBzd3SnaX6gcIV3\Wy|IHHmeIVzKDNiYX7kJFbDqGhib3[geJJm[XSvZX70 Mke2NlUyOjhyMkW=
RBE4 M{KxU2Z2dmO2aX;uJGF{e2G7 NYnw[pFVOsLizszN MYez5qCUOjUEoHi= MoHybY5kemWjc3XzJIFkfGm4ZTDjZZNx[XOnLUGyJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXyxsA> MV:yOVEzQDB{NR?=
RBE4 M4XPSmZ2dmO2aX;uJGF{e2G7 MUWyxsDPxE1? NIr5fZk{6oDVMkVCpIg> MWLpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCUT2OgeIlu\S2mZYDlcoRmdnSueR?= NVftVJllOjVzMkiwNlU>
RBE4 NH;STWdHfW6ldHnvckBCe3OjeR?= M17WelLDqM7:TR?= NWTIZ4llO+LCk{K0xsBp NH3wcWhqdmS3Y3XzJIEh\GWuYYnl[EBl\XCuZYTpc44hd2ZidHjlJGVTKEOjMjxCpINwdnSnboSgZZQhPsLiaDDv[kBqdmO3YnH0bY9vKHOrZ37p[olk[W62bIm= NEDRT|kzPTF{OECyOS=>
RBE4 M3vC[mZ2dmO2aX;uJGF{e2G7 MWmyxsDPxE1? M3X6PVPjiJN{NNMgbC=> NV:2R5Q5cW6mdXPld{BidiCxdnXycI9i\CCxZjDDZVIsyqCrbjD0bIUhdWm2b3Poc45lemmjIHnuJJRp\SCoaYLzeEA3yqCqIH;mJIlv[3WkYYTpc44hMHEkgJm85qCKOC5yMEGpJIJ2fCCFYUKrxsBt\X[nbIOgbY4hfGirczDvdodidmWubHWg[IVkemWjc3XkJIFnfGW{IEGyxsBpKG:oIHnuZ5Vj[XSrb36= M3z5SlI2OTJ6MEK1
Huh-7  M3n0eGZ2dmO2aX;uJGF{e2G7 NH\1eXIy|rypL33M MnLQN-KBmzJ2wrDo NVPwdZJpcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDBVGUyKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz MkG4NlUxOjZzN{S=
HepG2  NUfZU|ZjTnWwY4Tpc44hSXO|YYm= M1LhOVHPxGdxbVy= MVGz5qCUOjUEoHi= NInK[2dqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIFHQSVEhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> Mln3NlUxOjZzN{S=
H838-LKB1 MkXTSpVv[3Srb36gRZN{[Xl? NVrKeXB6OzEEoH7nM41t NILmUGoyOi9zODDo NUHnZ5M2cW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDCbXDDqA>? MUGyOVAyOTB6Mh?=
H838-KDLKB1  NVPMXZYzTnWwY4Tpc44hSXO|YYm= NXjHdo5OOzEEoH7nM41t NWe1SIhvOTJxMUigbC=> NGDFdGJqdmO{ZXHz[ZMhfGinIIDyc5RmcW5ibHX2[Yx{KG:oIFLpVOKh MX:yOVAyOTB6Mh?=
H838-KDLKB1  Mn3NSpVv[3Srb36gRZN{[Xl? MoW3N|DDqG6pL33s NWjQWo9SOTJxMUigbC=> NXnYUWFCcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdIhwe3Cqb4L5cIF1\WRiZVnGNu6yKCiyaH;zdIhwNWWLRkNOtUk> M3TpWFI2ODFzMEiy
3T3-L1 M360VWZ2dmO2aX;uJGF{e2G7 M1H0U|Uh|rypL33s NVvIPGliOzBibXnu MV3tbY1q[3NidHjlJIVn\mWldIOgc4YhcW6|dXzpckBidmRiY3H1d4V{KHKxYoXzeEBxcG:|cHjvdplt[XSrb36gc4YhSWu2IDjT[ZIhPDd|KTDhcoQheGixc4Doc5J6dGG2aX;uJI9nKEGVMU[wJEhVcHJiNkSyJIFv\CCVZYKgOVg5MQ>? MnzVNlQ5PDN6Mke=
3T3-L1 NVLOcXhyTnWwY4Tpc44hSXO|YYm= NV6w[mlKPSEQvHevcYw> MmPXN|AhdWmw Mo\0doVk[XCrdIXsZZRmeyCrboP1cIlvKGGldHnvckB4cXSqIILld5Bm[3RidH:gdoVofWyjdHnu[{BCc3RiYXP0bZZqfHliYX7kJGFUOTZyIIDoc5NxcG:{eXzheIlwdg>? MoDmNlQ5PDN6Mke=
3T3-L1 M2rx[WZ2dmO2aX;uJGF{e2G7 MnnPOUDPxGdxbXy= NFvvU|Y{OCCvaX6= MXTjZZV{\XNicnX2[ZJ{cWKuZTDy[YRqe3S{aXL1eIlwdiCxZjDHUHVVPA>? MWiyOFg1Ozh{Nx?=
3T3-L1 NEf6UFFHfW6ldHnvckBCe3OjeR?= M{PKfVUh|rypL33s MkH0NeKhcA>? NIC3T2Vk[XW|ZYOgdoVlcXO2cnnieZRqd25ib3[gS2xWXDRiYoX0JI5wfCCrbnPy[YF{\SCrbjDncJVkd3OnIIXweIFs\Q>? NV3GTHJrOjR6NEO4Nlc>
3T3-L1 MlyySpVv[3Srb36gRZN{[Xl? MoDsOUDPxGdxbXy= NEPWSHYyyqCq NXm0SlV6[2G3c3XzJJBpd3OyaH;yfYxifGmxbjDv[kB1cGViRn;4U|EhfHKjboPjdolxfGmxbjDmZYN1d3J? MmGzNlQ5PDN6Mke=
HeLa  MVPGeY5kfGmxbjDBd5NigQ>? NEXWN5c2KM7:Zz;tcC=> MV6zJIg> NInm[lVk[XW|ZYOgcpVkdGWjcjDlfINtfXOrb36gc4YhfGinIF\vfG8yKHS{YX7zZ5JqeHSrb36g[oFkfG:{IHHu[EBl\WO{ZXHz[ZMhfHKjboPjdolxfGmxbjDv[kBHd3iRMT3y[Yd2dGG2ZXSg[4Vv\XN? MWeyOFg1Ozh{Nx?=
HEK293 NWjr[FJ7TnWwY4Tpc44hSXO|YYm= MmrGOeKh|rypL33s M2rRNlEzyqCq MYrhZo9tcXOqZYOgR21CNWmwZIXj[YQhS1KHTFSyJJNm[3KndHnvci=> NES0RVYzPDZ6N{SzNS=>
COS-1 M4jmdmZ2dmO2aX;uJGF{e2G7 MofsOUDDvWdxbXy= NXPROpRSOjRiaNMg NVf5TpF[emW|dILpZ5R{KGyxY3HsbZpifGmxbjDv[kBPSiCrbjD0bIUheGW{aX71Z4xm[XJicnXnbY9vyqB? NIO3OFczPDZ5MUe1NS=>
PRP NH\TfJNHfW6ldHnvckBCe3OjeR?= M2PjU|ExKM7:TR?= NUO4UZd2[WK{b3fheIV{KFOGRj2x{tEudWWmaXH0[YQhS1iFUkeg[Zh1\XKwYXzpfoF1cW:wwrC= NFmyNVQzPDZ4OEe1NC=>
RAW264.7 NU\W[WNISXCxcITvd4l{KEG|c3H5 MXy0JO69VQ>? MlfOOFghcA>? M2j6W4F1fGWwdXH0[ZMhfGinIHnubIljcXSrb36gc4Yhd3hvTFTMMYlv\HWlZXSgZZBweHSxc3nzJIFv\CC2aHWg[oFkcWyrdHH0bY9vKG:oIHPoc4xme3Sncn;sJIVn\my3eDDifUBC[y2qRT2xPGEuVkh{ MlPTNlQ3OzlyM{K=
MDMs M4HzVmFxd3C2b4Ppd{BCe3OjeR?= NIf1N|EyOOLCid88[{9udA>? M3foZ|EzNzF3IHi= NVTJNW51cW6mdXPld{BieG:ydH;zbZM> NXu3TIs{OjR3NU[2PVU>
PMHs  MWnGeY5kfGmxbjDBd5NigQ>? NF\0fnIyOOLCk{Kw5qCK|rypL33s NGTU[FMzPOLCiXi= MUHEUXNQ M2nKVolv\HWlZXSgSXIhe3S{ZYPz Ml\oNlQ1ODd{NEK=
PMHs  NX\K[YZ3SXCxcITvd4l{KEG|c3H5 NIfYTFcyOOLCk{Kw5qCK|rypL33s NXTZVYJmOjUkgJno MX\EUXNQ M{iwTolv[3KnYYPld{Bk\WyuIHTlZZRp M1\ySlI1PDB5MkSy
HEK293/tau MVHGeY5kfGmxbjDBd5NigQ>? NUnnToFRPSEQvF2= NGPv[28yNzJxNDDo NXvWOmNIcW6mdXPld{BId2ypaTDmdoFodWWwdHH0bY9vyqB? NH7EUWszPDN4OEC4PS=>
HEK293/tau M{nieGZ2dmO2aX;uJGF{e2G7 NXjQPHdzPSEQvF2= NV6z[JJlOyCq MUXpcoR2[2W|IITheUBpgXCncoDoc5NxcG:{eXzheIlwdg>? NUHMN3hPOjR|NkiwPFk>
ADF NV;KXZVVTnWwY4Tpc44hSXO|YYm= MWqxNEDPxE1? MWWxOkBp NWPaXGpicW6qaXLpeJMhfGinIGruR4wzNWmwZIXj[YQhfHKjboPsc4NifGmxbjDv[kBEWlR? M3;jNFI1OjJ6MkOy
U373  NULDUWFsTnWwY4Tpc44hSXO|YYm= M3PYV|ExKM7:TR?= Ml\0NVYhcA>? MoLJbY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> MonrNlQzOjh{M{K=
RKO-HIPK2i M4rhSmZ2dmO2aX;uJGF{e2G7 NIXMRpUyOCEQvF2= NXTtVWFJOTZiaB?= NXTLVoROcW6qaXLpeJMhfGinIGruR4wzNWmwZIXj[YQhfHKjboPsc4NifGmxbjDv[kBEWlR? M3P4OlI1OjJ6MkOy
ADF  Ml3lSpVv[3Srb36gRZN{[Xl? M{\TTlExKM7:TdMg NF\RXW03KGh? MkG1bY1x[Wm{czD0bIUhTENiYXP0bZZifGmxbh?= NEXkc3IzPDJ{OEKzNi=>
Huh7 NFjBR2tHfW6ldHnvckBCe3OjeR?= MXu1JO69\y:vbB?= M3GyT|QhcA>? NFv0W4Vi[m:uaYPo[ZMhfGinIIPlZ5JmfGmxbjDv[kAhcW62cnHj[YxtfWyjcjDBdI9D NHfkU24zPDFyMEG0NC=>
Huh7 Mke3SpVv[3Srb36gRZN{[Xl? MYq1JO69\y:vbB?= NITXSmMyKGh? MojlZ4F2e2W|IHGgd4lodmmoaXPhcpQhcW6lcnXhd4UhcW5iQYDvRk1kemW|Y3XueJM> MmT2NlQyODBzNEC=
Huh7 MXvGeY5kfGmxbjDBd5NigQ>? MUK15qCUOTEEoH7nM41t MoHrNVIhcA>? M2DmbIlv[3KnYYPld{BCeG:ELXPy[ZNk\W62czD3bZRpd3W2IHnubIljcXSrbnegd4VkemW2aX;u MmPsNlQyODBzNEC=
BAECs NYi3fW5ZTnWwY4Tpc44hSXO|YYm= M4TO[VUh|rypL33s NXvUVVB6OC12IHi= MojLbY5lfWOnczD0bIUhemGyaXSg[IVxcG:|cHjvdplt[XSrb36gc4Yh\U6RUzDheEBU\XJzMUe5 MW[yOFA5PTJ{NR?=
Macrophages NVznemxYTnWwY4Tpc44hSXO|YYm= NEn4WJE4OSEEtV2= NHrOemg3KGh? MkX3bY5pcWKrdIOgcJVv[XOrbjDpcpRmem6jbHn6ZZRqd28EoB?= MonsNlQxOzl5NEC=
Colo 205 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1W2XlAuPSEQvHevcWw> MmjLOFghcA>? Mo\1bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5ic4XzdIVve2mxbjDjeYx1fXKnczD3bZRpKGGwIHXzeIlu[XSnZDDJR|UxKG:oII6xOUBv\y:vTB?= M4DwfVI{QTd|OUm2
Colo 205 NGjrb45HfW6ldHnvckBCe3OjeR?= MXWwMlAyOi1yLkCyOUDPxGdxbVy= NVXU[VIxOTRiZB?= MWHy[YR2[2W|IITo[UBkdG:wb3flcolkcXS7IH;mJGNwdG9iMkC1JGNUS3N? MmLINlM6PzN7OU[=
Colo 205 MoHmRZBweHSxc3nzJGF{e2G7 M3H2T|AvOSEQvHevcWw> NULaVFczOC1{NDDo NXzvWItKcW6mdXPld{BieG:ydH;zbZMhd2ZiQ3;sc{AzODViY3XscJMhcW5ic4XzdIVve2mxbjDjeYx1fXKncx?= M2HjdVI{QTd|OUm2
Colo 205 MnHESpVv[3Srb36gRZN{[Xl? M3XZ[FAvODF3IN88[{9uVA>? M2WzUFI1KGh? NGXqXplqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGVTKHO2cnXzd{1z\WyjdHXkJIdmdmW| MVmyN|k4Ozl7Nh?=
Colo 205 NEOzcJlHfW6ldHnvckBCe3OjeR?= MlvJNE4xOTVizsznM41N NY\wUZVMOjRiaB?= MmqybY5pcWKrdIOgeIhmKGGldHn2bZR6KG:oIF3NVJM> NF[2c3MzOzl5M{m5Oi=>
IBRS2 MljTSpVv[3Srb36gRZN{[Xl? NYjVU5lKPSEQvHevcYw> MlTwNE42KGh? MUPEUXNQ NFLFUmNlcXO{dYD0d{B1cGViRWLHTWMh[W6mIFfvcIdqyqB? M4C2ZlI{QTZ|NUO0
IBRS2 NFTYOGFHfW6ldHnvckBCe3OjeR?= MmnqOUDPxGdxbXy= NIjpPJQxNjViaB?= NUfqfIVOTE2VTx?= M4DPbIVvcGGwY3XzJGZOTFZiaX7m[YN1cW:w M12xNFI{QTZ|NUO0
HeLa M4jBd2Z2dmO2aX;uJGF{e2G7 NXXwUpV7OiEQvF2= M1;UZ|IhcMLi M3TXOYF1fGWwdXH0[ZMhfGinIGTOSk1qdmS3Y3XkJJNm[3KndHnvckBw\iCLTD2xOS=> M{Dm[|I{QTVyOEmy
HFS  NEC3VI9HfW6ldHnvckBCe3OjeR?= MYmwMVEh|rypL33s MXqyOEBp M3\PN2dNXFBiZYjwdoV{e2mxbjDy[YFkcGW|IHGgdIxifGWjdTDheEBkd26lZX70doF1cW:wczDhd{Btd3diYYOgNE4xOSEEtXevcYw> MXKyN|g6PDZ|Mx?=
HFS  NIPBSopHfW6ldHnvckBCe3OjeR?= NVvCWJZzOC5yMTFCuYcwdWx? M4nWUVI1KGh? MkLjbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIdtgWOxc4DobY5od2yrcHnkJJN6dnSqYYPlJIdmdmW|IHH0JFYhcA>? NVjFbXUyOjN6OUS2N|M>
OVCAR-3 Ml\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[x5qCUOTYEoN88UeKh M12zeFI1yqCq MW\pcoR2[2W|IHGgcI9{eyCxZjDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6yqB? NIOyOJAzOzh{Nkm2OC=>
OVCAR-3 M3PwbWZ2dmO2aX;uJGF{e2G7 NXHH[4VUOeLCk{G1xsDPxE4EoB?= NHuySWMzPMLiaB?= MUTpcoR2[2W|IH71Z4xm[XJiZHHtZYdm M2DlcVI{QDJ4OU[0
OVCAR-3 MlrHRZBweHSxc3nzJGF{e2G7 NGr1T3YyNTFywrFOwG0> NXvqdVczPCCq NXfrWm5KcW6mdXPld{B1cGViYXP0bZZifGmxbjDv[kBieG:ydH;zbZMuemWuYYTl[EBxem:2ZXnudy=> MoWyNlM5OjZ7NkS=
OVCAR-3 M1yze2Fxd3C2b4Ppd{BCe3OjeR?= Mmj4NVDDqM7:TR?= MmfMNlTDqGh? M1r1Solv\HWlZYOgZYN1cX[jdHnvckBw\iClYYPwZZNmew>? M4jmeFI{QDJ4OU[0
OVCAR-3 M4K4cGZ2dmO2aX;uJGF{e2G7 NULLVlBuOeLCk{GwxsDPxE1? MWqyOOKhcA>? M1q3d4lv\HWlZYOg[Il{enWydHnvckBw\iC2aHWgcYl1d2Oqb37kdolidCC2cnHud41mdWK{YX7lJJBwfGWwdHnhcC=> MVyyN|gzPjl4NB?=
OVCAR-3 MoHWSpVv[3Srb36gRZN{[Xl? NYXTRZhnOeLCk{GwxsDPxE1? NVi0SWp5OjUEoHi= MmHYbY5lfWOnczDmc5Ju[XSrb36gc4YhemWjY4TpeoUhd3i7Z3XuJJNx\WOrZYO= MnvpNlM5OjZ7NkS=
OVCAR-3 MV3GeY5kfGmxbjDBd5NigQ>? MnjaNgKBmzFywrFOwG0> NVW5doVKOjUEoHi= M1zBWIlvcGmkaYTzJINmdGxiYXTo[ZNqd25iYX7kJI1q\3KjdHnvci=> NEe0PI8zOzh{Nkm2OC=>
MKN45 NHjJfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRDBwMECxJO69\y:vbB?= NHvoNVkzOzd7M{O0Ni=>
LOVO NF7CPWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW4fI1KSzVyPUCuNVIh|rypL33s MlvkNlM4QTN|NEK=
A549 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDaTWM2OD1yLkC0JO69\y:vbB?= NFvNc4IzOzd7M{O0Ni=>
MDA-MB-435 NH\1[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjmcJROUUN3MEywMlAxOSEQvHevcYw> Mn;LNlM4QTN|NEK=
HepG2 M{PaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITFbXFKSzVyPECuNFAyKM7:Zz;tcC=> MmfuNlM4QTN|NEK=
HL-60 MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRDBwMECxJO69\y:vbB?= NXjJOYpTOjN5OUOzOFI>

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[5]
+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method: HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water <1 mg/mL
Ethanol <1 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID